文献速递肾移植

肾移植受者随机试验中癌症结局报告的范围与一致性

Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2022-11-08

该研究检索2000年2月至2021年7月ClinicalTrials.gov数据库,评估成人肾移植受者随机对照试验中癌症结局的定义与报告范围及一致性。819项肾移植试验中仅84项(10%)纳入至少1项癌症结局,其中72项(86%)将癌症作为次要结局、12项(14%)作为主要结局,最常见的描述为「恶性肿瘤」(44项,43%),未参考诊断标准、组织学、分级或分期。结论认为癌症是报告不频繁且定义不一致的结局,采用标准化定义一致报告癌症结局可提供肾移植后癌症影响的重要信息。

要点

  • 819项肾移植随机对照试验中仅84项(10%)纳入至少1项癌症结局
  • 84项中72项(86%)将癌症作为次要结局,12项(14%)作为主要结局
  • 最常见描述为「恶性肿瘤」(44项,43%),未参考诊断标准、组织学、分级或分期

核心结论

  • 癌症在肾移植受者试验中是报告不频繁的结局,且定义不一致。
  • 采用标准化定义一致报告癌症结局可提供肾移植后癌症影响的重要信息。

研究设计与样本

  • 检索ClinicalTrials.gov数据库2000年2月至2021年7月,纳入成人肾移植受者且将癌症列为特定结局的所有随机对照试验(RCTs)。
  • 共识别819项肾移植试验,其中84项(10%)纳入1项或以上癌症结局。
  • 提取每项癌症结局的定义、癌症类型(如有)、测量时间点和汇总方法。

主要发现

  • 819项肾移植试验中仅84项(10%)纳入1项或以上癌症结局。
  • 84项中72项(86%)将癌症作为次要结局,12项(14%)将癌症作为主要结局。
  • 最常见的癌症描述为「恶性肿瘤」(n=44,43%),未参考诊断标准、组织学、分级或分期。
  • 最常见的两种癌症类型为移植后淋巴增殖性疾病(PTLD)(n=20,20%)和非黑色素瘤皮肤癌(n=10,10%)。
  • 汇总方法包括发生率或率(n=47,46%)、频数或比例(n=30,29%)和至事件时间(n=5,5%);约半数癌症结局在单一时间点测量(n=44,52%)。

关键数值与推荐

  • 仅84项(10%)肾移植随机对照试验纳入1项或以上癌症结局。
  • 72项(86%)将癌症作为次要结局,12项(14%)作为主要结局。
  • 「恶性肿瘤」描述44项(43%),未参考诊断标准、组织学、分级或分期。
  • 移植后淋巴增殖性疾病(PTLD)20项(20%),非黑色素瘤皮肤癌10项(10%)。
  • 发生率或率47项(46%),频数或比例30项(29%),至事件时间5项(5%);单一时间点测量44项(52%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cancer is an important outcome in kidney transplantation, but the scope and consistency of how cancer is defined and reported in trials involving kidney transplant recipients has not been evaluated. This study aimed to assess the range and variability of cancer outcomes in trials involving kidney transplant recipients. METHODS: The ClinicalTrials.gov database was searched from February 2000 to July 2021 to identify all randomized controlled trials (RCTs) in adult kidney transplant recipients, and which included cancer as a specified outcome. The definition of cancer, types of cancer (if any), timepoint(s) of measurement and method of aggregation were extracted for each cancer outcome. RESULTS: Of the 819 trials in kidney transplantation, only 84 (10%) included 1 or more cancer outcomes. Of these, 72 of 84 (86%) trials included cancer as a secondary outcome and 12 of 84 (14%) considered cancer as a primary outcome. The most frequent description of cancer was "malignancy" (n = 44, 43%), without reference to diagnostic criteria, histology, grade, or stage. The 2 most common cancer types were posttransplant lymphoproliferative disorder (PTLD) (n = 20, 20%) and nonmelanoma skin cancer (n = 10, 10%). Several methods of aggregation were identified, including incidence or rate (n = 47, 46%), frequency or proportion (n = 30, 29%), and time to event (n = 5, 5%). Approximately half the cancer outcomes were measured at a single time point (n = 44, 52%). CONCLUSION: Cancer is an infrequently reported outcome and is inconsistently defined in trials of kidney transplant recipients. Consistent reporting of cancer outcomes using standardized definitions would provide important information on the impact of cancer in patients after kidney transplantation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Au EH, Wong G, Tong A, et al. Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients. Kidney Int Rep. 2022. PMID: 36815120. doi:10.1016/j.ekir.2022.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。